 |
|
|
| |
Adverse Event Profile of the Interferon-free All-oral ABT-450/r/Ombitasvir, Dasabuvir, and Ribavirin Regimen in HCV Patients
|
| |
| |
Reported by Jules Levin
54th Annual Interscience Conference on Anti microbial Agents and Chemotherapy, September 5-9, 2014, Washington, DC
Donald M Jensen1, Tolga Baykal2, Eric Lawitz3, Jordan J Feld4, Gioacchino Angarano5, Saumya Jayakumar6, Tania M Welzel7, Eoin Coakley2, Bo Fu2, Barbara Da Silva-Tillmann2, Lois Larsen2
1Center for Liver Diseases, University of Chicago Medical Center, Chicago, Illinois, United States; 2AbbVie Inc., North Chicago, Illinois, United States; 3The Texas Liver Insti tute, University of Texas Health Science Center, San Antonio, Texas, United States; 4Toronto Centre for Liver Disease, University of Toronto, Toronto, Ontario, Canada; 5University of Bari, Bari, Italy; 6University of Calgary, Calgary, Alberta, Canada; 7JW Goethe University, Frankfurt, Germany
|
| |
|
|
|
|
|
